WO2011093828A2 - Formes posologiques solides comprenant du cefprozil - Google Patents

Formes posologiques solides comprenant du cefprozil Download PDF

Info

Publication number
WO2011093828A2
WO2011093828A2 PCT/TR2011/000032 TR2011000032W WO2011093828A2 WO 2011093828 A2 WO2011093828 A2 WO 2011093828A2 TR 2011000032 W TR2011000032 W TR 2011000032W WO 2011093828 A2 WO2011093828 A2 WO 2011093828A2
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
composition according
sodium
cefprozil
tablet
Prior art date
Application number
PCT/TR2011/000032
Other languages
English (en)
Other versions
WO2011093828A3 (fr
Inventor
Mahmut Bilgic
Original Assignee
Mahmut Bilgic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mahmut Bilgic filed Critical Mahmut Bilgic
Publication of WO2011093828A2 publication Critical patent/WO2011093828A2/fr
Publication of WO2011093828A3 publication Critical patent/WO2011093828A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Definitions

  • the present invention relates to solid oral dosage forms comprising cefprozil and/or pharmaceutically acceptable salts, hydrates, solvates, esters, amorphous and crystal forms and/or a combination of these.
  • Cefprozil which is a second generation cephalosporin, was first disclosed in the patent numbered US4520022 and its chemical name is 8-[2-amino-2-(4-hydroxyphenyl)-acetyl] amino-7-oxo-4-prop-l-enyl-2-thia-6- azabicyclo [4.2.0]oct-4-ene-5-carboxylic acid.
  • Cefprozil shown with Formula 1 is indicated for use in treatment of bronchitis, ear infections, skin infections and for treatment of other infections.
  • Cefprozil is marketed as 250 mg and 500 mg oral dosage forms.
  • tablets comprising 250 mg and 500 mg of active ingredient are formulated with excipients into a single dosage, the tablets become too big and this makes the resulting dosage forms unfit for use in patients with swallowing difficulties, especially in pediatric and geriatric patients.
  • Suspensions are prepared to overcome the aforementioned problems; however the suspensions do not seem to be preferable since they lead to uncontrolled dose intake and there are problems related to their physical and chemical stabilities after they are diluted with water. Moreover, they have high cost of production and they cause problems while using and transferring.
  • Present invention relates to water soluble powders, tablets and granules comprising cefprozil and/or pharmaceutically acceptable salts, hydrates, solvates, esters, amorphous and crystal forms and/or a mixture of these and formulations comprising them and processes related to their preparation. It was found that water soluble powders, tablets and granules comprising cefprozil as active ingredient and are formulated according to the formulation disclosed in the present invention, dissolve in water completely and form a homogenous and pleasant tasting cefprozil solution.
  • pharmaceutical dosage forms that are in water soluble powder, tablet or granule form and prepared for single dose use; a) Has a longer shelf life compared to the medications in suspension form, since they are in solid dosage form that is more stable, and
  • water soluble powder, tablet and granules of the present invention combine advantages of both tablets and suspensions and eliminates the problems arising from these.
  • the term "water soluble powder, tablet, granule” comprises effervescent tablets, effervescent granules, effervescent powders, water soluble tablets, water soluble powders, water soluble granules, water dispersible tablets, water dispersible powders and water dispersible granules.
  • one aspect of the present invention is water soluble powder, tablet and granules comprising cefprozil as active ingredient.
  • Another aspect of the invention is, water soluble powder, tablet and granule formulations comprising pharmaceutically acceptable excipients in addition to cefprozil that is used as the active ingredient.
  • Cefprozil which will be used in water soluble powder, tablet and granule formulations of the present invention can be in form of its solvates, hydrates, esters, enantiomers, racemates, organic salts, inorganic salts, polymorphs, crystal and amorphous forms or in free acid form and/or a combination of these.
  • Water soluble formulations in addition to cefprozil, may comprise excipients such as binders, lubricants, humidity absorbers, disintegrants, diluents, basic agents, acidic agents, sweeteners, taste regulating agents and optionally effervescent couple.
  • excipients such as binders, lubricants, humidity absorbers, disintegrants, diluents, basic agents, acidic agents, sweeteners, taste regulating agents and optionally effervescent couple.
  • the excipients should not be limited with the ones disclosed herein.
  • the binder which can be used in water soluble powder, tablet and granule formulations prepared according to present invention can be selected from, but not limited with, a group comprising ethyl cellulose, gelatine, hydroxyethyl cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, hypromellose, magnesium aluminum silicate, methylcellulose and povidon.
  • the lubricant which can be used in water soluble powder, tablet and granule formulations prepared according to present invention can be selected from, but not limited with, a group comprising calcium stearate, magnesium stearate, polyethylene glycol, PEG 6000, polyvinyl alcohol, potassium benzoate and sodium benzoate.
  • the humidity absorber which can be used in water soluble powder, tablet and granule formulations prepared according to present invention can be selected from, but not limited with, a group comprising anhydrous sodium sulfate, silica gel and potassium carbonate.
  • the disintegrant which can be used in water soluble powder, tablet and granule formulations prepared according to present invention can be selected from, but not limited with, a group comprising carboxymethylcellulose calcium, carboxymethylcellulose sodium, microcrystalline cellulose, silicon dioxide, croscarmellose sodium, crospovidon, hydroxypropyl cellulose, methylcellulose, povidone, magnesium aluminum silicate and starch.
  • the diluent which can be used in water soluble powder, tablet and granule formulations prepared according to present invention can be selected from, but not limited with, a group comprising calcium carbonate, calcium sulfate, microcrystalline cellulose, lactose, magnesium carbonate, magnesium oxide, maltodextrin, maltose, mannitol, sodium chloride, sorbitol, starch and xylitol or combinations thereof.
  • the basic agent which can be used in water soluble powder, tablet and granule formulations prepared according to present invention can be selected from, but not limited with, a group comprising potassium carbonate, potassium bicarbonate, potassium citrate, potassium hydroxide, sodium carbonate, sodium bicarbonate, or combinations thereof.
  • the acidic agent which can be used in water soluble powder, tablet and granule formulations prepared according to present invention can be selected from, but not limited with, a group comprising acetic acid, citric acid, lactic acid, malic acid, phosphoric acid, propionic acid, tartaric acid or combinations thereof.
  • the sweetener which can be used in water soluble powder, tablet and granule formulations prepared according to present invention can be selected from, but not limited with, a group comprising acesulfame, aspartamate, dextrose, fructose, glucose, lactitol, maltitol, maltose, sorbitol, saccharine, saccharine sodium, sodium cyclamate, sucralose, sodium chloride, potassium chloride, sucrose, xylitol or combinations thereof.
  • the effervescent couple which can optionally be used in water soluble powder, tablet and granule formulations prepared according to present invention can be selected from a group comprising organic acids such as citric acid, tartaric acid, malic acid, fumaric acid, etc. and basic agents such as sodium hydrogen carbonate, sodium carbonate, potassium carbonate and potassium hydrogen carbonate.
  • organic acids such as citric acid, tartaric acid, malic acid, fumaric acid, etc.
  • basic agents such as sodium hydrogen carbonate, sodium carbonate, potassium carbonate and potassium hydrogen carbonate.
  • water soluble powder, tablet and granule formulations according to present invention 50- 5000 mg of cefprozil or its pharmaceutically acceptable salts, hydrates, solvates or combinations thereof in amounts equivalent to this can be used.
  • present invention relates to processes that can be used for preparation of water soluble powder, tablet and granule formulations which comprise cefprozil and in addition to that pharmaceutically acceptable excipients.
  • a process according to present invention comprises granulation of excipients with conventional wet and/or dry granulation methods present in the state of the art and drying them and afterwards addition of cefprozil into this granule mixture and dry blending of the formed mixture and preferably compression of the final mixture in tablet pressing machine to obtain tablets.
  • Water soluble tablets according to present invention can be prepared according to the examples given below. The examples are given for demonstrating the invention and the invention cannot be limited with these.
  • EXAMPLE 1 Formulation and process for preparation of effervescent tablet
  • Formulation according to present invention can be obtained by granulation of effervescent couple, sweetener (2), binder and drying of the formed granules and then mixing the granulate with cefprozil and sweetener (1) and then addition of flavoring agent and lubricant to the formed mixture. The final mixture is compressed in tablet pressing machine to give tablet forms.
  • present invention is related to use of water soluble formulations comprising cefprozil and in addition to that pharmaceutically acceptable excipients for treatment of infections caused by gram positive and gram negative bacteria.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des formes posologiques orales solides comprenant du cefprozil et/ou ses sels pharmaceutiquement acceptables, hydrates, solvates, esters, formes amorphes et formes cristallines et/ou une combinaison de ceux-ci.
PCT/TR2011/000032 2010-01-29 2011-01-28 Formes posologiques solides comprenant du cefprozil WO2011093828A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2010/00689A TR201000689A1 (tr) 2010-01-29 2010-01-29 Sefprozil içeren katı dozaj formlar.
TR2010/00689 2010-01-29

Publications (2)

Publication Number Publication Date
WO2011093828A2 true WO2011093828A2 (fr) 2011-08-04
WO2011093828A3 WO2011093828A3 (fr) 2012-02-23

Family

ID=44065360

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/TR2011/000032 WO2011093828A2 (fr) 2010-01-29 2011-01-28 Formes posologiques solides comprenant du cefprozil
PCT/TR2011/000036 WO2011093831A2 (fr) 2010-01-29 2011-01-31 Formulations effervescentes contenant du cefprosil comme principe actif

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/TR2011/000036 WO2011093831A2 (fr) 2010-01-29 2011-01-31 Formulations effervescentes contenant du cefprosil comme principe actif

Country Status (3)

Country Link
EP (1) EP2528593A2 (fr)
TR (1) TR201000689A1 (fr)
WO (2) WO2011093828A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102357086A (zh) * 2011-11-01 2012-02-22 上海理工大学 一种头孢丙烯口腔崩解片
WO2013109201A1 (fr) * 2012-01-18 2013-07-25 Mahmut Bilgic Compositions pharmaceutiques comprenant du cefprozil et de l'acide clavulanique
CN114886859A (zh) * 2022-06-09 2022-08-12 哈尔滨凯程制药有限公司 一种头孢丙烯颗粒剂

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111658616B (zh) * 2020-05-22 2022-03-15 广州白云山医药集团股份有限公司白云山制药总厂 一种头孢丙烯干混悬剂及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4520022A (en) 1983-01-28 1985-05-28 Bristol-Myers Company Substituted vinyl cephalosporins

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2311734C (fr) * 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Forme pharmaceutique orale a dissolution ultra-rapide
CN100417383C (zh) * 2006-03-07 2008-09-10 中国药科大学 一种含有头孢克肟的泡腾片及制法
CN101032489B (zh) * 2006-03-08 2011-06-15 上海秀新臣邦医药科技有限公司 头孢丙烯分散片及其制备方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4520022A (en) 1983-01-28 1985-05-28 Bristol-Myers Company Substituted vinyl cephalosporins

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102357086A (zh) * 2011-11-01 2012-02-22 上海理工大学 一种头孢丙烯口腔崩解片
WO2013109201A1 (fr) * 2012-01-18 2013-07-25 Mahmut Bilgic Compositions pharmaceutiques comprenant du cefprozil et de l'acide clavulanique
CN114886859A (zh) * 2022-06-09 2022-08-12 哈尔滨凯程制药有限公司 一种头孢丙烯颗粒剂

Also Published As

Publication number Publication date
WO2011093828A3 (fr) 2012-02-23
EP2528593A2 (fr) 2012-12-05
WO2011093831A3 (fr) 2012-02-23
TR201000689A1 (tr) 2011-08-22
WO2011093831A2 (fr) 2011-08-04

Similar Documents

Publication Publication Date Title
EP2528594B1 (fr) Formulations effervescentes contenant de la céphalosporine de deuxième génération
WO2012060788A1 (fr) Formulations de céphalosporines avec teneur en humidité contrôlée
WO2011093828A2 (fr) Formes posologiques solides comprenant du cefprozil
EP2515850B1 (fr) Compositions pharmaceutiques comprenant cefdinir comme principe
WO2011139249A2 (fr) Composition pharmaceutique renfermant du cefdinir
EP2566449B1 (fr) Compositions pharmaceutiques comprenant du ceftibutène
WO2011142730A1 (fr) Composition pharmaceutique comprenant la céfixime et un composé dérivé de l'acide clavulanique
WO2011129792A1 (fr) Formulations dispersibles dans l'eau comprenant le cefpodoxime proxétil
WO2012060786A2 (fr) Formulations de proxétil cefpodoxime comprenant un agent de viscosité
EP2608776A2 (fr) Préparations de cefpodoxime proxétil
EP2566451B1 (fr) Composition pharmaceutique contentant de cefditoren pivoxil
WO2011093829A1 (fr) Compositions effervescentes comprenant du cefixime et de l'acide clavulanique comme principes actifs
WO2011078828A1 (fr) Composition pharmaceutique très pure
EP2515859A1 (fr) Formulation effervescente à dispersion rapide
KR101446129B1 (ko) 프란루카스트-함유 고형 제제의 제조방법
WO2012060787A1 (fr) Comprimés contenant du cefdinir
WO2011139255A2 (fr) Compositions pharmaceutiques comprenant du céfétamet
WO2012060791A2 (fr) Procédé de production de compositions pharmaceutiques comprenant du cefdinir
WO2012060792A1 (fr) Compositions pharmaceutiques comprenant au minimum 6% en poids de délitants
WO2013109201A1 (fr) Compositions pharmaceutiques comprenant du cefprozil et de l'acide clavulanique
EP2663289A2 (fr) Préparations de cefpodoxime proxétil comprenant un agent régulateur de goût
WO2012078121A2 (fr) Forme posologique orale solide comprenant cefdinir
WO2012060793A2 (fr) Procédé de préparation de formulations de cefdinir
WO2011139250A2 (fr) Formulation hydrodispersable

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11713894

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11713894

Country of ref document: EP

Kind code of ref document: A2